K2 Principal Fund’s NextCure NXTC Stock Holding History

K2 Principal Fund’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-131,776	Closed	-$4.19M	–	297
2022 Q3	$4.19M	Buy	131,776 +66,082	+101%	+$3.37M	0.48%	57
2022 Q2	$3.71M	Buy	+65,694	New	+$3.43M	0.41%	66

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

K2 Principal Fund's NXTC Position: Q4 2022 in Review

K2 Principal Fund sold out of NextCure (NXTC) in Q4 2022, closing a stake of 131,776 shares — an estimated $4.19M sold.

K2 Principal Fund first reported a position in NXTC in Q2 2022 and held it in 2 quarters. The position peaked at $4.19M in Q3 2022. 45 funds tracked by Wall St. Rank hold NXTC as of Q4 2022.

K2 Principal Fund reported no remaining NextCure position as of Q4 2022 after selling out during the quarter.
K2 Principal Fund sold 131,776 NextCure shares in Q4 2022, an estimated $4.19M.
K2 Principal Fund first reported a position in NextCure in Q2 2022 and held it in 2 quarters.
K2 Principal Fund's NextCure position peaked at $4.19M in Q3 2022.
45 funds tracked by Wall St. Rank held NextCure as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.